Navigation Links
VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
Date:1/7/2008

associated with this disease. Despite currently available medications that treat the conditions that increase the risk of these events, these therapies do not treat the underlying inflammation."

The company provided the following specific update for each of its three Phase 2 clinical trials:

FDG-PET Study

The FDG-PET trial is enrolling approximately 50 patients following a heart attack into a 24 week randomized, double blind, placebo-controlled study. Enrollment is expected to be complete during 2008 and data is expected in the first half of 2009. Endpoints in the study include reduction in plaque inflammation following dosing with VIA-2291 as measured with FDG-PET, as well as assessment of standard biomarker measurements of inflammation. The use of state-of-the art FDG-PET imaging technology provides a new and important methodology for measuring the effect of VIA-2291 in reducing vascular inflammation.

"We are pleased with the progress of our clinical program and the commencement of our third Phase 2 trial to directly demonstrate the impact of VIA-2291 on inflammation in patients with advanced atherosclerotic disease," said Adeoye Olukotun, MD, chief medical officer of VIA. "The data from this study, in combination with our other two trials, is designed to directly assess the safety, mode of action and clinical activity of VIA-2291 to reduce vascular inflammation, and therefore, the risk of major adverse cardiovascular events."

The first patient was randomized to treatment at Massachusetts General Hospital in Boston. Mount Sinai Heart in New York City is also participating in the study.

Carotid Endarterectomy (CEA) Study

VIA has enrolled approximately 40 patients in the CEA study as planned, and is expanding enrollment to gather additional data by taking advantage of additional patients currently in the screening and patient recruitment process. VIA plans to enroll approximately 50 patients and expects to report data
'/>"/>

SOURCE VIA Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... YORK , 22 de mayo de ... DPRX ), una compañía farmacéutica de ... comercialización de Locilex® (pexiganan cream 0.8%), y ... una presentación de póster destacando el diseño ... 3 de la Compañía que evalúan Locilex®, ...
(Date:5/22/2015)... 22, 2015 The Assistance Fund announces the ... provides financial assistance for copay to individuals diagnosed with ... the addition of the Melanoma Copay Assistance Program to ... , executive director. "With each additional program we are ... world where no one is denied access to medications ...
(Date:5/22/2015)... May 22, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), ... repair and regeneration, today announced that J.J. Finkelstein ... present a corporate overview at two upcoming investor conferences. ... SeeThruEquity 4 th Annual Microcap Conference on Thursday ... at 11:00 am EDT.  A webcast will ...
Breaking Medicine Technology:Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 2Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 3Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 4Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 5Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 6The Assistance Fund Adds Melanoma Assistance Program 2RegeneRx to Present at 2 Investor Conferences 2RegeneRx to Present at 2 Investor Conferences 3
... England, March 8, 2012 Circassia Ltd, ... that its ragweed allergy therapy has achieved positive results ... study, patients with more severe symptoms achieved a significantly ... than those on placebo (p≤0.05).  The results were presented ...
... 8, 2012 Sosei Group Corporation ("Sosei"; ... that its wholly owned Japanese subsidiary, Sosei Co., Ltd., ... for the treatment of oropharyngeal candidiasis. SO-1105 was originally ... received its first marketing authorization for SO-1105 in France ...
Cached Medicine Technology:Circassia's Ragweed Allergy Therapy Achieves Positive Phase II Clinical Results 2Circassia's Ragweed Allergy Therapy Achieves Positive Phase II Clinical Results 3Sosei Announces Initiation of Phase I Study for SO-1105 2
(Date:5/23/2015)... On May 16, the team at Farrell’s eXtreme Bodyshaping ... obstacle run that raised funds for multiple sclerosis. , ... reason we participated was to support people living with MS ... Bodyshaping. “One-hundred percent of the funds raised go to benefit ... only attended by eXtreme Bodyshaping staff, but members of the ...
(Date:5/23/2015)... (PRWEB) May 23, 2015 Javon ... at the Sports Medicine and Rehabilitation Center, 557 N. ... program, Mondays, June 1-July 20, 5:30-6:30 pm. , The ... coach, and Laurie Finke, RN, BSN, who will offer ... education on nutrition, running mechanics and show selection and ...
(Date:5/22/2015)... Calif. (PRWEB) May 22, 2015 ... technology, communication and capacity are intersecting to create ... across society, the opening speaker at WesternU's 34th ... California Lieut. Gov. Gavin Newsom, a former San ... the keynote speaker at the graduation ceremony for ...
(Date:5/22/2015)... Lehi, Utah (PRWEB) May 22, 2015 Mountain ... will host a ribbon cutting ceremony on Friday, May 29, ... 1 p.m. to 6 p.m. The new medical center, set ... 3000 North Triumph Boulevard, Lehi, UT 84043. , “The ... for our team and the Utah County community,” said Kent ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 Following yesterday’s ... sale agreement with US-based health brand Nature’s Way, Marc ... brand. Retention of Ascenta Skin is an integral part ... excited about this opportunity to further develop Ascenta Skin ... , Ascenta Skin is a breakthrough, anti-aging skincare supplement ...
Breaking Medicine News(10 mins):Health News:Farrell’s eXtreme Bodyshaping Team Runs through the Muck for MS 2Health News:Newsom to WesternU Grads: The Future is Inside You 2Health News:Newsom to WesternU Grads: The Future is Inside You 3Health News:Mountain Point Medical Center, a Campus of Jordan Valley Medical Center, Hosts Ribbon Cutting Ceremony and Community Celebration on Friday, May 29, 2015 2Health News:Ascenta Skin President Announces Plans to Grow Brand 2
... July 21 The Neutraceutical Company, LLC (TNC -- www.tncllc.com ... exclusive rights to direct market a remarkable new extract of an ... ways for centuries. This new, 100% natural product is the latest ... helping people cope with everyday health concerns. , ...
... , , BALTIMORE, July 21 ... to people that want to take control of their health, and ... to employers announced that they have reached an agreement to bring ... their employees - "stay healthy." , , ...
... , LONDON, July 21 Europe,s aging population ... diagnoses of respiratory diseases. While there has been a shift towards ... profit margins in this highly price sensitive market, while providing technologically ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) , , ...
... , Project SHALEM: Partnering with the Faith-Based ... , BALTIMORE, July 21 Today, the ... at the University of Maryland School of Medicine, in partnership with ... Project SHALEM during City Uprising Baltimore ...
... , , , , ... DGX ), the world,s leading provider of diagnostic testing, ... 30, 2009, income from continuing operations rose to $188 million, or ... share, for the second quarter of 2008. These results include a ...
... , Project SHALEM: Partnering with ... , , BALTIMORE, July 21 ... Virology (IHV) at the University of Maryland School of Medicine, in ... organizations kicked-off Project SHALEM during City Uprising ...
Cached Medicine News:Health News:The Neutraceutical Company Announces Powerful New 'Feel-Good' Product 2Health News:Stayhealthy and Innovative Wellness Solutions Announce Partnership to Bring Innovation to the Workplace Wellness Market 2Health News:Stayhealthy and Innovative Wellness Solutions Announce Partnership to Bring Innovation to the Workplace Wellness Market 3Health News:Frost & Sullivan Examines the Key Challenges in the European Non-Invasive Ventilation Market 2Health News:JACQUES Initiative Joins Maryland AIDS Administration to Extend HIV Testing to the Faith-Based Community 2Health News:JACQUES Initiative Joins Maryland AIDS Administration to Extend HIV Testing to the Faith-Based Community 3Health News:JACQUES Initiative Joins Maryland AIDS Administration to Extend HIV Testing to the Faith-Based Community 4Health News:Quest Diagnostics Reports Strong Performance in Second Quarter 2009 2Health News:Quest Diagnostics Reports Strong Performance in Second Quarter 2009 3Health News:Quest Diagnostics Reports Strong Performance in Second Quarter 2009 4Health News:Quest Diagnostics Reports Strong Performance in Second Quarter 2009 5Health News:Quest Diagnostics Reports Strong Performance in Second Quarter 2009 6Health News:Quest Diagnostics Reports Strong Performance in Second Quarter 2009 7Health News:Quest Diagnostics Reports Strong Performance in Second Quarter 2009 8Health News:Quest Diagnostics Reports Strong Performance in Second Quarter 2009 9Health News:Quest Diagnostics Reports Strong Performance in Second Quarter 2009 10Health News:Quest Diagnostics Reports Strong Performance in Second Quarter 2009 11Health News:Quest Diagnostics Reports Strong Performance in Second Quarter 2009 12Health News:Quest Diagnostics Reports Strong Performance in Second Quarter 2009 13Health News:Quest Diagnostics Reports Strong Performance in Second Quarter 2009 14Health News:JACQUES Initiative Joins Maryland AIDS Administration to Extend HIV Testing to the Faith-Based Community 2Health News:JACQUES Initiative Joins Maryland AIDS Administration to Extend HIV Testing to the Faith-Based Community 3Health News:JACQUES Initiative Joins Maryland AIDS Administration to Extend HIV Testing to the Faith-Based Community 4
... operating and recovery room, ,The Cardiocap ... haemodynamic and airway gas monitoring for induction ... units. The Cardiocap II is available in ... haemodynamic measurements. Two of the models include ...
Precordial Chestpieces are manufactured from chrome plated brass. Provides a hollow design with deep sound chambers for optimum acoustics....
For accurately monitoring heart and breath sounds....
For accurately monitoring core temperature and heart and breath sounds....
Medicine Products: